Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment

Stock Information for Selecta Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Selecta Biosciences Inc.

Annovis Publishes Historical Review of Buntanetap in The Scientist
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
Annovis Announces Two Presentations at the AD/PD(TM) 2026 International Conference
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients
Annovis to Host Corporate Update Webinar on January 28, 2026

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.